 "Cipla hikes stake in US-based Chase Pharmaceuticals to 16.7%")
Cipla (EU) Ltd, the UK-based wholly-owned subsidiary of Cipla Ltd, has made an additional investment of $ 3 million (about Rs 20 crores) in the US-based Chase Pharmaceuticals to increase its stake from present 14.6 percent to 16.7 percent. In May 2014, Cipla had invested $1.5 million in Chase Pharmaceuticals, which is an early stage drug development company developing novel approaches to improve treatments for Alzheimer's disease, to acquire 14.6 percent.
“Cipla (EU) Ltd, UK, a wholly-owned subsidiary of the company made an additional investment of $3 million in Chase Pharmaceuticals towards full settlement of its obligation under the agreement arrangement for investment in Chase,” Cipla said in a BSE filing on March 15, 2016.
Consequently, Cipla UK's total investment in Chase would aggregate to approximately $5.12 million for a 16.7 percent stake on a fully diluted basis.
As per the agreement signed in May 2014, Cipla had agreed to make an additional $4.5 million investment in Chase upon achievement of certain milestones.
“Cipla (EU) Ltd, UK, a wholly-owned subsidiary of the company made an additional investment of $3 million in Chase Pharmaceuticals towards full settlement of its obligation under the agreement arrangement for investment in Chase,” Cipla said in a BSE filing on March 15, 2016.
Consequently, Cipla UK's total investment in Chase would aggregate to approximately $5.12 million for a 16.7 percent stake on a fully diluted basis.
As per the agreement signed in May 2014, Cipla had agreed to make an additional $4.5 million investment in Chase upon achievement of certain milestones.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%